Skip to content
PubMed This is a summary of 40 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 40 referenced papers

Top Authors

Evan E. Eichler
Howard Hughes Medical Institute
Raphael Bernier
University of Washington
Amélie Piton
Centre National de la Recherche Scientifique
Evangeline C. Kurtz‐Nelson
Indiana University School of Medicine
Rachel K. Earl
University of Washington
Emily Neuhaus
University of Washington
Caitlin M. Hudac
University of South Carolina
Bertrand Isidor
Centre National de la Recherche Scientifique
Marjolaine Willems
Centre Hospitalier Universitaire de Montpellier
Jean‐Louis Mandel
Centre National de la Recherche Scientifique

Top Institutions

Ranked by publications Top 10 institutions
04
05

Indiana University School of Medicine

Indianapolis, United States

9 papers
07

Assistance Publique – Hôpitaux de Paris

Paris, France

14 papers
10

References

References (40)
  1. 1

    DYRK1A mutations in two unrelated patients.

    Ruaud L, Mignot C, Guët A, et al.

    European journal of medical genetics 2015; (58(3)):168-74.

    PMID: 25641759
  2. 2

    Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID.

    van Bon BW, Coe BP, Bernier R, et al.

    Molecular psychiatry 2016; (21(1)):126-32 doi:10.1038/mp.2015.5.

    PMID: 25707398
  3. 3

    Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.

    Bronicki LM, Redin C, Drunat S, et al.

    European journal of human genetics : EJHG 2015; (23(11)):1482-7 doi:10.1038/ejhg.2015.29.

    PMID: 25920557
  4. 4

    DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.

    Ji J, Lee H, Argiropoulos B, et al.

    European journal of human genetics : EJHG 2015; (23(11)):1473-81 doi:10.1038/ejhg.2015.71.

    PMID: 25944381
  5. 5

    Angelman Syndrome.

    Margolis SS, Sell GL, Zbinden MA, Bird LM

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2015; (12(3)):641-50 doi:10.1007/s13311-015-0361-y.

    PMID: 26040994
  6. 6

    Familial recurrences of FOXG1-related disorder: Evidence for mosaicism.

    McMahon KQ, Papandreou A, Ma M, et al.

    American journal of medical genetics. Part A 2015; (167A(12)):3096-102 doi:10.1002/ajmg.a.37353.

    PMID: 26364767
  7. 7

    Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.

    Luco SM, Pohl D, Sell E, et al.

    BMC medical genetics 2016; (17()):15 doi:10.1186/s12881-016-0276-4.

    PMID: 26922654
  8. 8

    Angelman syndrome in Hong Kong Chinese: A 20 years' experience.

    Luk HM, Lo IF

    European journal of medical genetics 2016; (59(6-7)):315-9.

    PMID: 27174604
  9. 9

    Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.

    Stringer M, Abeysekera I, Thomas J, et al.

    Physiology & behavior 2017; (177()):230-241 doi:10.1016/j.physbeh.2017.05.003.

    PMID: 28478033
  10. 10

    Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism.

    Widowati EW, Ernst S, Hausmann R, et al.

    Biology open 2018; (7(4)) doi:10.1242/bio.032862.

    PMID: 29700199
  11. 11

    Copy-number variants in clinical genome sequencing: deployment and interpretation for rare and undiagnosed disease.

    Gross AM, Ajay SS, Rajan V, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(5)):1121-1130 doi:10.1038/s41436-018-0295-y.

    PMID: 30293986
  12. 12

    DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.

    De Toma I, Ortega M, Aloy P, et al.

    Frontiers in molecular neuroscience 2019; (12()):272 doi:10.3389/fnmol.2019.00272.

    PMID: 31803016
  13. 13

    A De Novo Mutation in DYRK1A Causes Syndromic Intellectual Disability: A Chinese Case Report.

    Qiao F, Shao B, Wang C, et al.

    Frontiers in genetics 2019; (10()):1194 doi:10.3389/fgene.2019.01194.

    PMID: 31803247
  14. 14

    DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.

    Meissner LE, Macnamara EF, D'Souza P, et al.

    Molecular genetics & genomic medicine 2020; (8(12)):e1544 doi:10.1002/mgg3.1544.

    PMID: 33159716
  15. 15

    Ocular Phenotype Associated with DYRK1A Variants.

    Méjécase C, Way CM, Owen N, Moosajee M

    Genes 2021; (12(2)) doi:10.3390/genes12020234.

    PMID: 33562844
  16. 16

    Detailed Clinical and Psychological Phenotype of the X-linked HNRNPH2-Related Neurodevelopmental Disorder.

    Bain JM, Thornburg O, Pan C, et al.

    Neurology. Genetics 2021; (7(1)):e551 doi:10.1212/NXG.0000000000000551.

    PMID: 33728377
  17. 17

    Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.

    Levy JA, LaFlamme CW, Tsaprailis G, et al.

    Biological psychiatry 2021; (90(5)):295-306 doi:10.1016/j.biopsych.2021.01.012.

    PMID: 33840455
  18. 18

    Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).

    Manickam K, McClain MR, Demmer LA, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(11)):2029-2037 doi:10.1038/s41436-021-01242-6.

    PMID: 34211152
  19. 19

    Clinical course of epilepsy and white matter abnormality linked to a novel DYRK1A variant.

    Okazaki T, Yamada H, Matsuura K, et al.

    Human genome variation 2021; (8(1)):26 doi:10.1038/s41439-021-00157-7.

    PMID: 34253714
  20. 20

    Characterization of phenotypic range in DYRK1A haploinsufficiency syndrome using standardized behavioral measures.

    Fenster R, Ziegler A, Kentros C, et al.

    American journal of medical genetics. Part A 2022; (188(7)):1954-1963 doi:10.1002/ajmg.a.62721.

    PMID: 35285131
  21. 21

    Social motivation a relative strength in DYRK1A syndrome on a background of significant speech and language impairments.

    Morison LD, Braden RO, Amor DJ, et al.

    European journal of human genetics : EJHG 2022; (30(7)):800-811 doi:10.1038/s41431-022-01079-w.

    PMID: 35437318
  22. 22

    Interventions for Transition-Age Youth With Disabilities: A Meta-Analysis of Group Design Studies.

    Crowley S

    American journal on intellectual and developmental disabilities 2022; (127(3)):169-193 doi:10.1352/1944-7558-127.3.169.

    PMID: 35443051
  23. 23

    Neurocognitive and neurobehavioral characterization of two frequent forms of neurodevelopmental disorders: the DYRK1A and the Wiedemann-Steiner syndromes.

    Durand B, Schaefer E, Burger P, et al.

    Clinical genetics 2022; (102(4)):296-304 doi:10.1111/cge.14190.

    PMID: 35821609
  24. 24

    Characterizing Sensory Phenotypes of Subgroups with a Known Genetic Etiology Pertaining to Diagnoses of Autism Spectrum Disorder and Intellectual Disability.

    Hudac CM, Friedman NR, Ward VR, et al.

    Journal of autism and developmental disorders 2024; (54(6)):2386-2401 doi:10.1007/s10803-023-05897-9.

    PMID: 37031308
  25. 25

    A delayed intervention start randomized controlled trial of high- and low-tech communication training approaches for school-age autistic children with co-occurring intellectual disability.

    Gilroy SP, McCleery JP, Leader G

    Journal of applied behavior analysis 2023; (56(3)):593-606 doi:10.1002/jaba.989.

    PMID: 37092868
  26. 26

    Case report: A novel de novo deletion mutation of DYRK1A is associated with intellectual developmental disorder, autosomal dominant 7.

    Zhou C, Zhu H, Xiang Q, et al.

    Frontiers in neuroscience 2023; (17()):1174925 doi:10.3389/fnins.2023.1174925.

    PMID: 37274198
  27. 27

    Characterizing the autism spectrum phenotype in DYRK1A-related syndrome.

    Kurtz-Nelson EC, Rea HM, Petriceks AC, et al.

    Autism research : official journal of the International Society for Autism Research 2023; (16(8)):1488-1500 doi:10.1002/aur.2995.

    PMID: 37497568
  28. 28

    Growth charts in DYRK1A syndrome.

    Lanvin PL, Goronflot T, Isidor B, et al.

    American journal of medical genetics. Part A 2024; (194(1)):9-16 doi:10.1002/ajmg.a.63412.

    PMID: 37740550
  29. 29

    Identification of two novel and one rare mutation in DYRK1A and prenatal diagnoses in three Chinese families with intellectual Disability-7.

    Huang C, Luo H, Zeng B, et al.

    Frontiers in genetics 2023; (14()):1290949 doi:10.3389/fgene.2023.1290949.

    PMID: 38179410
  30. 30

    A Rare Cause of Intellectual Disability.

    Oliveira Í, Fernandes A, Pereira M, et al.

    Cureus 2024; (16(1)):e51451 doi:10.7759/cureus.51451.

    PMID: 38298296
  31. 31

    Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly.

    Herbst C, Bothe V, Wegler M, et al.

    Human genetics 2024; (143(3)):455-469 doi:10.1007/s00439-024-02655-4.

    PMID: 38526744
  32. 32

    Shared and divergent mental health characteristics of ADNP-, CHD8- and DYRK1A-related neurodevelopmental conditions.

    Neuhaus E, Rea H, Jones E, et al.

    Journal of neurodevelopmental disorders 2024; (16(1)):15 doi:10.1186/s11689-024-09532-1.

    PMID: 38622540
  33. 33

    Two remarkable cases of haploinsufficiency found in the DYRK1A gene.

    Taşdelen E, Tekbaş UC, Baş H, Sezer A

    Acta neurologica Belgica 2025; (125(3)):839-843 doi:10.1007/s13760-024-02685-9.

    PMID: 39572511
  34. 34

    Characterizing executive functioning and associated behaviors in individuals with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) syndrome.

    Rea HM, Webb SJ, Kurtz-Nelson EC, et al.

    Frontiers in neuroscience 2024; (18()):1485499 doi:10.3389/fnins.2024.1485499.

    PMID: 39840013
  35. 35

    DYRK1A roles in human neural progenitors.

    Courraud J, Quartier A, Drouot N, et al.

    Frontiers in neuroscience 2025; (19()):1533253 doi:10.3389/fnins.2025.1533253.

    PMID: 40182141
  36. 36

    Clinical and molecular overlap between nucleotide excision repair (NER) disorders and DYRK1A haploinsufficiency syndrome.

    Le May N, Courraud J, Boujelbène I, et al.

    Frontiers in neuroscience 2025; (19()):1554093 doi:10.3389/fnins.2025.1554093.

    PMID: 40206408
  37. 37

    DYRK1A syndrome presenting with a familial exudative vitreoretinopathy (FEVR)-like retinovascular phenotype.

    Lin S, Hay E, Thompson DA, et al.

    Ophthalmic genetics 2025; (46(4)):389-393 doi:10.1080/13816810.2025.2503388.

    PMID: 40405340
  38. 38

    The role of Goldilocks protein kinase DYRK1A in embryonic development.

    Johnson HK, Litovchick LL, Dickinson AJG

    Developmental biology 2025; (525()):216-228 doi:10.1016/j.ydbio.2025.06.009.

    PMID: 40505942
  39. 39

    Episignature leads to diagnosis and reclassification of DYRK1A variant in a child with syndromic neurodevelopmental disorder: a case report.

    Al-Younis I, Basque L, Crapoulet N, et al.

    Frontiers in genetics 2026; (17()):1813300 doi:10.3389/fgene.2026.1813300.

    PMID: 42256340
  40. 40

    DYRK1A - a gene dose paradox.

    Plećaš A, Gough G, Kunštek S, et al.

    Frontiers in cell and developmental biology 2026; (14()):1963992 doi:10.3389/fcell.2026.1963992.

    PMID: 42909264